FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1971888253> ?p ?o ?g. }

• W1971888253 abstract "Abstract Background Aggressive non-melanoma skin cancer (deeply infiltrating, recurrent, and morphea form lesions) are therapeutically challenging because they require considerable tissue loss and may demand radical disfiguring surgery. Interferons (IFN) may provide a non-surgical approach to the management of these tumors. The aim of this work was to evaluate the effect of a formulation containing IFNs-α and -γ in synergistic proportions on patients with recurrent, advanced basal cell (BCC) or squamous cell skin carcinomas (SCSC). Methods Patients with extensive, recurrent, resistant to other procedures BCC or SCSC received the IFN formulation peri- and intralesionally, three times per week for 3 weeks. They had been previously treated with surgery and/or radiotherapy or chemotherapy. Thirteen weeks after the end of treatment, the original lesion sites were examined for histological evidence of remaining tumor. Results Sixteen elder (median 70 years-old) patients were included. They beared 12 BCC and 4 SCSC ranging from 1.5 to 12.5 cm in the longest dimension. At the end of treatment 47% CR (complete tumor elimination), 40% PR (>30% tumor reduction), and 13% stable disease were obtained. None of the patients relapsed during the treatment period. The median duration of the response was 38 months. Only one patient with complete response had relapsed until today. Principal adverse reactions were influenza-like symptoms well known to occur with interferon therapy, which were well tolerated. Conclusion The peri- and intralesional combination of IFNs-α and -γ was safe and showed effect for the treatment of advanced, recurrent and resistant to previous treatments of BCC and SCSC in elder patients. This is the first report of such treatment in patients with advance non-melanoma skin cancer. The encouraging result justifies further confirmatory trials. Trial registration Current Controlled Trials RPCEC00000052." @default.
• W1971888253 created "2016-06-24" @default.
• W1971888253 creator A5008440586 @default.
• W1971888253 creator A5029528798 @default.
• W1971888253 creator A5060234412 @default.
• W1971888253 creator A5067727981 @default.
• W1971888253 creator A5075745597 @default.
• W1971888253 date "2009-07-30" @default.
• W1971888253 modified "2023-09-24" @default.
• W1971888253 title "Treatment of advanced, recurrent, resistant to previous treatments basal and squamous cell skin carcinomas with a synergistic formulation of interferons. Open, prospective study" @default.
• W1971888253 cites W1505088803 @default.
• W1971888253 cites W1964016716 @default.
• W1971888253 cites W1967060514 @default.
• W1971888253 cites W1973830935 @default.
• W1971888253 cites W1979856281 @default.
• W1971888253 cites W1985185561 @default.
• W1971888253 cites W1991746877 @default.
• W1971888253 cites W2002494043 @default.
• W1971888253 cites W2003755223 @default.
• W1971888253 cites W2004599969 @default.
• W1971888253 cites W2008976442 @default.
• W1971888253 cites W2009108535 @default.
• W1971888253 cites W2009419236 @default.
• W1971888253 cites W2011235392 @default.
• W1971888253 cites W2012999486 @default.
• W1971888253 cites W2017449430 @default.
• W1971888253 cites W2021737287 @default.
• W1971888253 cites W2022317665 @default.
• W1971888253 cites W2035096716 @default.
• W1971888253 cites W2053740411 @default.
• W1971888253 cites W2058072615 @default.
• W1971888253 cites W2066931485 @default.
• W1971888253 cites W2072532644 @default.
• W1971888253 cites W2075616620 @default.
• W1971888253 cites W2080476062 @default.
• W1971888253 cites W2084340499 @default.
• W1971888253 cites W2088973205 @default.
• W1971888253 cites W2096231077 @default.
• W1971888253 cites W2101008161 @default.
• W1971888253 cites W2105820114 @default.
• W1971888253 cites W2111595593 @default.
• W1971888253 cites W2116097769 @default.
• W1971888253 cites W2116996913 @default.
• W1971888253 cites W2122421907 @default.
• W1971888253 cites W2141465943 @default.
• W1971888253 cites W2141756791 @default.
• W1971888253 cites W2155341746 @default.
• W1971888253 cites W2156011594 @default.
• W1971888253 cites W2156647222 @default.
• W1971888253 cites W2162489686 @default.
• W1971888253 cites W4241391812 @default.
• W1971888253 cites W4252865728 @default.
• W1971888253 cites W4256189622 @default.
• W1971888253 cites W98489723 @default.
• W1971888253 doi "https://doi.org/10.1186/1471-2407-9-262" @default.
• W1971888253 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2724551" @default.
• W1971888253 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19643007" @default.
• W1971888253 hasPublicationYear "2009" @default.
• W1971888253 type Work @default.
• W1971888253 sameAs 1971888253 @default.
• W1971888253 citedByCount "24" @default.
• W1971888253 countsByYear W19718882532012 @default.
• W1971888253 countsByYear W19718882532013 @default.
• W1971888253 countsByYear W19718882532014 @default.
• W1971888253 countsByYear W19718882532016 @default.
• W1971888253 countsByYear W19718882532017 @default.
• W1971888253 countsByYear W19718882532018 @default.
• W1971888253 countsByYear W19718882532020 @default.
• W1971888253 countsByYear W19718882532021 @default.
• W1971888253 crossrefType "journal-article" @default.
• W1971888253 hasAuthorship W1971888253A5008440586 @default.
• W1971888253 hasAuthorship W1971888253A5029528798 @default.
• W1971888253 hasAuthorship W1971888253A5060234412 @default.
• W1971888253 hasAuthorship W1971888253A5067727981 @default.
• W1971888253 hasAuthorship W1971888253A5075745597 @default.
• W1971888253 hasBestOaLocation W19718882531 @default.
• W1971888253 hasConcept C126322002 @default.
• W1971888253 hasConcept C141071460 @default.
• W1971888253 hasConcept C143998085 @default.
• W1971888253 hasConcept C197934379 @default.
• W1971888253 hasConcept C2776694085 @default.
• W1971888253 hasConcept C2777658100 @default.
• W1971888253 hasConcept C2778804307 @default.
• W1971888253 hasConcept C2780140570 @default.
• W1971888253 hasConcept C3019992690 @default.
• W1971888253 hasConcept C502942594 @default.
• W1971888253 hasConcept C509974204 @default.
• W1971888253 hasConcept C71924100 @default.
• W1971888253 hasConcept C90924648 @default.
• W1971888253 hasConceptScore W1971888253C126322002 @default.
• W1971888253 hasConceptScore W1971888253C141071460 @default.
• W1971888253 hasConceptScore W1971888253C143998085 @default.
• W1971888253 hasConceptScore W1971888253C197934379 @default.
• W1971888253 hasConceptScore W1971888253C2776694085 @default.
• W1971888253 hasConceptScore W1971888253C2777658100 @default.
• W1971888253 hasConceptScore W1971888253C2778804307 @default.
• W1971888253 hasConceptScore W1971888253C2780140570 @default.
• W1971888253 hasConceptScore W1971888253C3019992690 @default.
• W1971888253 hasConceptScore W1971888253C502942594 @default.
• W1971888253 hasConceptScore W1971888253C509974204 @default.

• next